• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

    12/16/21 10:20:26 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email
    New Drug Application (NDA): 016750
    Company: AMPHASTAR PHARMS INC
    • Email

    Products on NDA 016750

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    CORTROSYN COSYNTROPIN 0.25MG/VIAL INJECTABLE;INJECTION Prescription AP Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 016750

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    04/22/1970 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD

    Label is not available on this site.

    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    12/14/2021 SUPPL-32 Labeling-Container/Carton Labels Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/016750Orig1s032lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/016750Orig1s032ltr.pdf
    09/29/2014 SUPPL-28 Manufacturing (CMC)

    Label is not available on this site.

    11/05/2002 SUPPL-18 Labeling Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/16750slr018ltr.pdf
    12/07/2000 SUPPL-17 Manufacturing (CMC)-Control

    Label is not available on this site.

    03/18/1999 SUPPL-16 Manufacturing (CMC)-Control

    Label is not available on this site.

    01/09/1998 SUPPL-15 Labeling

    Label is not available on this site.

    01/29/1997 SUPPL-14 Manufacturing (CMC)

    Label is not available on this site.

    04/08/1997 SUPPL-13 Manufacturing (CMC)-Control

    Label is not available on this site.

    02/18/1994 SUPPL-12 Manufacturing (CMC)

    Label is not available on this site.

    04/28/1989 SUPPL-10 Labeling

    Label is not available on this site.

    10/28/1988 SUPPL-9 Manufacturing (CMC)

    Label is not available on this site.

    05/09/1988 SUPPL-8 Manufacturing (CMC)-Control

    Label is not available on this site.

    02/26/1987 SUPPL-7 Manufacturing (CMC)-Control

    Label is not available on this site.

    05/08/1987 SUPPL-6 Manufacturing (CMC)-Control

    Label is not available on this site.

    02/10/1987 SUPPL-5 Manufacturing (CMC)-Control

    Label is not available on this site.

    04/02/1986 SUPPL-4 Labeling

    Label is not available on this site.

    10/26/1982 SUPPL-3 Manufacturing (CMC)

    Label is not available on this site.

    04/28/1982 SUPPL-2 Manufacturing (CMC)-Control

    Label is not available on this site.

    Labels for NDA 016750

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    12/14/2021 SUPPL-32 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/016750Orig1s032lbl.pdf

    Therapeutic Equivalents for NDA 016750

    CORTROSYN

    INJECTABLE;INJECTION; 0.25MG/VIAL
    TE Code = AP

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    CORTROSYN COSYNTROPIN 0.25MG/VIAL INJECTABLE;INJECTION Prescription Yes AP 016750 AMPHASTAR PHARMS INC
    COSYNTROPIN COSYNTROPIN 0.25MG/VIAL INJECTABLE;INJECTION Prescription No AP 090574 MYLAN INSTITUTIONAL
    COSYNTROPIN COSYNTROPIN 0.25MG/VIAL INJECTABLE;INJECTION Prescription No AP 202147 SANDOZ
    Get the next $AMPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    8/12/2025$36.00Hold → Buy
    Needham
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    10/21/2022$36.00Buy
    Jefferies
    More analyst ratings

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Petersen Floyd F. sold $15,492 worth of shares (500 units at $30.98), decreasing direct ownership by 0.65% to 76,531 units (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    9/3/25 4:20:45 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Petersen Floyd F. sold $10,416 worth of shares (500 units at $20.83), decreasing direct ownership by 0.64% to 77,031 units (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    8/4/25 7:17:46 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gaugh David Russell was granted 6,304 shares (SEC Form 4)

    4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

    7/22/25 4:23:29 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

    1/8/25 6:00:00 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/26/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/13/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Amphastar Pharmaceuticals upgraded by Needham with a new price target

    Needham upgraded Amphastar Pharmaceuticals from Hold to Buy and set a new price target of $36.00

    8/12/25 7:45:35 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals downgraded by Analyst with a new price target

    Analyst downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $30.00

    5/12/25 8:19:14 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $36.00 from $66.00 previously

    2/4/25 6:58:07 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AMPH
    SEC Filings

    View All

    FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

    1/26/24 4:40:02 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

    12/27/23 4:38:39 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

    6/30/23 9:33:25 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Amphastar Pharmaceuticals Inc.

    144 - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    9/2/25 4:08:33 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    8/12/25 6:10:42 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.

    10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

    8/7/25 4:43:01 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Financials

    Live finance-specific insights

    View All

    Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

    1/8/25 6:00:00 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/26/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

    11/13/24 4:05:00 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    3/6/24 10:23:26 AM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    2/13/24 4:58:53 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

    2/9/24 5:21:50 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care